DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

Vision - Conquer prostate cancer

Prostate Cancer Cover Image
» Click on Image to View Program Booklet
PCRP Strategic Plan Image
» Click on Image to View Strategic Plan

Prostate cancer is the most commonly diagnosed non-skin cancer in men and is the second most common cause of male death from cancer. In 2018, approximately 164,690 men in the U.S. will be diagnosed with prostate cancer and an estimated 29,430 will die from it1. Prostate cancer is a real threat to U.S. Service members, as 80% of the active duty population are men. According to the Defense Health Agency (DHA) Medical Surveillance Monthly Report (MSMR), 8,973 new cancers were diagnosed among active duty members of the U.S. Armed Forces between 2005 and 2014, and of these, 1,046 (11.7%) were prostate cancer diagnoses. Prostate cancer incidence, morbidity, and mortality rates also vary markedly by race and ethnicity, with African American (AA) men experiencing the highest rates in the U.S.

Since 1997, the Prostate Cancer Research Program (PCRP) has been dedicated to supporting research focused on eradicating prostate cancer, and specifically seeks to promote:

  • Highly innovative, groundbreaking research
  • High-impact research with near-term clinical relevance
  • The next generation of prostate cancer investigators through mentored research
  • Resources that will facilitate translational research

The PCRP has developed a strategic plan that outlines the program’s approach for addressing critical gaps in prostate cancer research and patient care. Currently, the PCRP seeks to address the following Overarching Challenges:
  • Develop treatments that improve outcomes for men with lethal prostate cancer
  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations
  • Define the biology of lethal prostate cancer to reduce death
  • Improve the quality of life for survivors of prostate cancer

1American Cancer Society (https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html)


Congressional Appropriations

Congressional Appropriations

  • $1.62 billion
    FY97-FY17
  • $100 million
    FY18

Related Videos

Dr. Karen Sfanos


Johns Hopkins University
A Relationship Between Mast Cells and Racial Disparity of Prostate Cancer

Dr. Bettina Drake


Washington University in St. Louis
Prostate Cancer Outcomes in VA Hospitals

The CDMRP Grant Review Process: Maximizing Success



2016 Prostate Cancer IMPaCT Meeting Highlights



Dr. Colin Pritchard

University of Washington
Hypermutation and Genomic Testing for Precision Therapy in Advanced Prostate Cancer

Dr. Himisha Beltran

Weill Cornell Medicine
Divergent Clonal Evolution of Castration Resistant Neuroendocrine Prostate Cancer

Last updated Friday, September 14, 2018